search
Back to results

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Abrocitinib 200 MG Oral Tablet
Ritlecitinib
Placebo
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring TrialNet, T1D

Eligibility Criteria

12 Years - 35 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Provide informed consent or assent as appropriate and, if < 18 years of age have a parent or legal guardian provide informed consent Age 12-35 years (both inclusive) at the time of signing informed consent and assent Diagnosis of T1D within 100 days of the baseline visit (V0). Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A Stimulated C-peptide of ≥0.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes HbA1c ≤ 10 % Body weight ≥ 35kg at screening Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM) Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0). Be up to date on recommended immunizations; participants are required to receive killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when vaccine for the current or upcoming flu season is available. Enrollment must be delayed at least 4 weeks from administration of a killed vaccine other than influenza and 6 weeks from a live vaccination. Vaccinations should not be given while on study drug and be postponed at least 3 months after the last dose of study drug. Participants are required to be fully vaccinated including eligible boosters and should receive an authorized non-live COVID-19 vaccination series or COVID-19 vaccine at least 2 weeks prior to the baseline visit (V0). If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly-effective contraceptive method for the duration of the study Males of reproductive age must use a highly-effective contraceptive method during the treatment phase and for 3 months following last dose of study drug Exclusion Criteria: Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8 Untreated hypothyroidism or active Graves' disease Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0 Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0 a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment Have active signs or symptoms of acute infection at the time of the baseline visit (V0). Significant trauma or major surgery within 1 month of signing informed consent. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster Have evidence of prior or current tuberculosis infection as assessed by Purified Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history Have evidence of current or past HIV or Hepatitis B infection Have evidence of active Hepatitis C infection Have current, confirmed COVID-19 infection Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other thromboembolic events or history of inherited coagulopathies First degree relative with a history of unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), which suggests that a participant may be at increased risk of inherited coagulation disorder Any present malignancies or history of malignancy, other than a successfully treated nonmelanoma skin cancer History of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting in classification as a poor CYP2C19 metabolizer). Have renal impairment (eGFR< 60 mL/min, MDRD) Currently on anti-platelet therapies, excluding low dose aspirin One or more screening laboratory values as stated Neutrophils < 1,500 /μL Lymphocytes < 800 /μL Platelets < 150,000 / μL Hemoglobin < 6.2 mmol/L (10.0 g/dL) Potassium > 5.5 mmol/L or <3.0 mmol/L Sodium > 150mmol/L or < 130mmol/L AST or ALT ≥ 2.5 times the upper limit of normal Bilirubin ≥ 1.5 times upper limit of normal unless diagnosed with Gilbert's syndrome LDL >160 mg/dL Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine and COVID vaccine) Be currently pregnant or lactating or anticipate becoming pregnant during the study Male participants able to father children and female participants of childbearing potential who are unwilling or unable to use 2 effective methods (at least 1 highly effective method) of contraception, including abstinence, as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product Be currently participating in another T1D treatment study Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and any history of cerebrovascular disease within 24 weeks before screening; Heart failure NYHA (New York Heart Association) III, NYHA IV ANY of the following conditions at screening: a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease (eg, cardiomyopathy, Wolff-Parkinson- White syndrome); ii. Confirmed QT corrected using Fridericia's correction factor (QTcF) prolongation (>450 milliseconds). b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de Pointes (TdP). History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse within 2 years prior to screening Current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day Participant is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results

Sites / Locations

  • Barbara Davis Center at University of Colorado Anschutz Medical CampusRecruiting
  • Yale University School of MedicineRecruiting
  • University of FloridaRecruiting
  • University of MinnesotaRecruiting
  • University of PittsburghRecruiting
  • Benaroya Research InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Abrocitinib

Ritlecitinib

Placebo

Arm Description

Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.

Ritlecitnib will be self-administered via oral administration as a 100-mg capsule daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.

200 mg tablet or 100 mg capsule matching either abrocitinib or ritlecitinib will be self-administered via oral administration daily for 52 weeks (12 months). The final product is to be labeled to protect the blind.

Outcomes

Primary Outcome Measures

The area under the stimulated C-peptide curve (Y_AUC)
The primary outcome of interest is the area under the stimulated C-peptide curve over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit (Y_AUC) over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit.

Secondary Outcome Measures

Full Information

First Posted
February 3, 2023
Last Updated
September 7, 2023
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT05743244
Brief Title
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Official Title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
June 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Detailed Description
This study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
TrialNet, T1D

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants aged 12-35 years will be randomized 1:1:1 to receive abrocitinib, ritlecitinib, and placebo. The planned design is to enroll 26 participants in each of the 3 arms: the abrocitinib arm, the ritlecitinib arm, and the shared placebo arm. Within the shared placebo arm, participants will be randomized 1:1 to receive placebo matched to abrocitinib or placebo matched to ritlecitinib. Randomization will be stratified by the following two age categories: 12-17 years old, and 18 years or above. Within each stratum, participants will be randomized to either the abrocitinib arm, ritlecitinib arm, or the shared placebo arm using random block sizes. The total number of enrolled participants from the older age stratum (18 years or above) will be limited to 33 to replicate the age distribution in previous new-onset trials. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo then enter a follow-up period of up to 12 months.
Masking
ParticipantCare ProviderInvestigator
Masking Description
The randomization method will be stratified by TrialNet study site. The participants will not be informed regarding the intervention assignment until the end of the study. The investigator and clinic personnel will also be masked as to study assignment. Laboratories performing assays for this protocol will be masked as to the identity of biological material to be studied.
Allocation
Randomized
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Abrocitinib
Arm Type
Experimental
Arm Description
Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
Arm Title
Ritlecitinib
Arm Type
Experimental
Arm Description
Ritlecitnib will be self-administered via oral administration as a 100-mg capsule daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
200 mg tablet or 100 mg capsule matching either abrocitinib or ritlecitinib will be self-administered via oral administration daily for 52 weeks (12 months). The final product is to be labeled to protect the blind.
Intervention Type
Drug
Intervention Name(s)
Abrocitinib 200 MG Oral Tablet
Other Intervention Name(s)
CIBINQO
Intervention Description
Abrocitinib
Intervention Type
Drug
Intervention Name(s)
Ritlecitinib
Intervention Description
Ritlecitinib
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for Abrocitinib or Ritlecitinib
Primary Outcome Measure Information:
Title
The area under the stimulated C-peptide curve (Y_AUC)
Description
The primary outcome of interest is the area under the stimulated C-peptide curve over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit (Y_AUC) over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit.
Time Frame
12 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provide informed consent or assent as appropriate and, if < 18 years of age have a parent or legal guardian provide informed consent Age 12-35 years (both inclusive) at the time of signing informed consent and assent Diagnosis of T1D within 100 days of the baseline visit (V0). Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A Stimulated C-peptide of ≥0.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes HbA1c ≤ 10 % Body weight ≥ 35kg at screening Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM) Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0). Be up to date on recommended immunizations; participants are required to receive killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when vaccine for the current or upcoming flu season is available. Enrollment must be delayed at least 4 weeks from administration of a killed vaccine other than influenza and 6 weeks from a live vaccination. Vaccinations should not be given while on study drug and be postponed at least 3 months after the last dose of study drug. Participants are required to be fully vaccinated including eligible boosters and should receive an authorized non-live COVID-19 vaccination series or COVID-19 vaccine at least 2 weeks prior to the baseline visit (V0). If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly-effective contraceptive method for the duration of the study Males of reproductive age must use a highly-effective contraceptive method during the treatment phase and for 3 months following last dose of study drug Exclusion Criteria: Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8 Untreated hypothyroidism or active Graves' disease Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0 Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0 a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment Have active signs or symptoms of acute infection at the time of the baseline visit (V0). Significant trauma or major surgery within 1 month of signing informed consent. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster Have evidence of prior or current tuberculosis infection as assessed by Purified Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history Have evidence of current or past HIV or Hepatitis B infection Have evidence of active Hepatitis C infection Have current, confirmed COVID-19 infection Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other thromboembolic events or history of inherited coagulopathies First degree relative with a history of unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), which suggests that a participant may be at increased risk of inherited coagulation disorder Any present malignancies or history of malignancy, other than a successfully treated nonmelanoma skin cancer History of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting in classification as a poor CYP2C19 metabolizer). Have renal impairment (eGFR< 60 mL/min, MDRD) Currently on anti-platelet therapies, excluding low dose aspirin One or more screening laboratory values as stated Neutrophils < 1,500 /μL Lymphocytes < 800 /μL Platelets < 150,000 / μL Hemoglobin < 6.2 mmol/L (10.0 g/dL) Potassium > 5.5 mmol/L or <3.0 mmol/L Sodium > 150mmol/L or < 130mmol/L AST or ALT ≥ 2.5 times the upper limit of normal Bilirubin ≥ 1.5 times upper limit of normal unless diagnosed with Gilbert's syndrome LDL >160 mg/dL Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine and COVID vaccine) Be currently pregnant or lactating or anticipate becoming pregnant during the study Male participants able to father children and female participants of childbearing potential who are unwilling or unable to use 2 effective methods (at least 1 highly effective method) of contraception, including abstinence, as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product Be currently participating in another T1D treatment study Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and any history of cerebrovascular disease within 24 weeks before screening; Heart failure NYHA (New York Heart Association) III, NYHA IV ANY of the following conditions at screening: a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease (eg, cardiomyopathy, Wolff-Parkinson- White syndrome); ii. Confirmed QT corrected using Fridericia's correction factor (QTcF) prolongation (>450 milliseconds). b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de Pointes (TdP). History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse within 2 years prior to screening Current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day Participant is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jessica S Conaty
Phone
8133969234
Email
Jessica.Conaty@epi.usf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Parker
Phone
8133969378
Email
Melissa.Parker@epi.usf.edu
Facility Information:
Facility Name
Barbara Davis Center at University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morgan Sooy
Phone
303-724-5686
Email
MORGAN.SOOY@CUANSCHUTZ.EDU
First Name & Middle Initial & Last Name & Degree
Andrea Steck, MD
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcia DeSousa
Phone
203-737-4805
Email
marcia.desousa@yale.edu
First Name & Middle Initial & Last Name & Degree
Jennifer L. Sherr, MD
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Hosford
Phone
352-294-5759
Email
jennifer.hosford@medicine.ufl.edu
First Name & Middle Initial & Last Name & Degree
Danielle Poulton
Phone
352-294-5761
Email
Danielle.Poulton@medicine.ufl.edu
First Name & Middle Initial & Last Name & Degree
Michael J Haller, MD
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kali Johnson
Phone
612-624-6682
Email
joh13933@umn.edu
First Name & Middle Initial & Last Name & Degree
Toni Moran, MD
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kelli DeLallo
Phone
412-692-5210
Email
kelli.delallo@chp.edu
First Name & Middle Initial & Last Name & Degree
Ingrid Libman, MD
Facility Name
Benaroya Research Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Corinna Tordillos
Phone
206-341-8937
Email
ctordillos@benaroyaresearch.org
First Name & Middle Initial & Last Name & Degree
Sandra Lord, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be available at the NIDDK Central Repository
Links:
URL
http://www.diabetestrialnet.org
Description
TrialNet

Learn more about this trial

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

We'll reach out to this number within 24 hrs